{Reference Type}: Journal Article
{Title}: [Translated article] Diagnosis of tuberculous infection in immunosuppressed patients and/or candidates for biologics using a combination of 2 IGRA tests: T-SPOT.TB/QuantiFERON TB Gold In-Tube vs. T-SPOT.TB/QuantiFERON TB Gold Plus.
{Author}: Fernández-Blázquez A;Argüelles Menéndez P;Sabater-Cabrera C;García-García JM;Asensi Álvarez V;Palacios Gutiérrez JJ; ;Fernández-Blázquez A;Argüelles Menéndez P;Sabater-Cabrera C;García-García JM;Asensi Álvarez V;Palacios Gutiérrez JJ; ;Fernández-Blázquez A;Argüelles Menéndez P;Sabater-Cabrera C;García-García JM;Asensi Álvarez V;Palacios Gutiérrez JJ; ;
{Journal}: Arch Bronconeumol
{Volume}: 58
{Issue}: 4
{Year}: Apr 2022
{Factor}: 6.333
{DOI}: 10.1016/j.arbres.2020.04.026
{Abstract}: <B>BACKGROUND: </B>The diagnosis of latent tuberculous infection (LTI) by IGRA continues to generate debate. Experience in the simultaneous use of 2 IGRA tests is scant. The aim of this study was to compare the results of 2 versions of QuantiFERON-TB Gold (In-Tube/Plus) with those of T-SPOT.TB, and to analyse the effectiveness of a dual strategy (T-SPOT.TB + QTF) for the diagnosis of LTI in an immunosuppressed population.<BR><B>METHODS: </B>We conducted a prospective study (May 2015-June 2017) that included 2999 immunosuppressed patients and/or candidates for biologics, in whom 2 simultaneous IGRA tests were performed: Group 1 (1535 patients): T-SPOT.TB + QuantiFERON-TB Gold-In-Tube (QTF-GIT); Group 2 (1464 patients): T-SPOT.TB + QuantiFERON-TB Gold Plus (QTF-Plus.<BR><B>RESULTS: </B>The concordance between QTF-GIT and T-SPOT.TB was 83.19% (κ = 0.532). The percentage of positive, negative, and indeterminate results were, respectively: 14.33% vs. 17.06%; 82.41% vs. 74.46%; and 3.25% vs. 8.46%. The concordance between QTF-Plus and T-SPOT.TB was 87.56% (κ = 0.609). The percentage of positive, negative, and indeterminate results were, respectively: 15.02% vs. 15.36%; 82.92% vs. 79.37%; and 2.04% vs. 5.25%. Discrepancies between T-SPOT.TB and QTF-Plus were 12.43%, suggesting that 103 patients were positive and another 79 were negative due exclusively to 1 of the 2 IGRAs.<BR><B>CONCLUSIONS: </B>Greater concordance was found between QTF-Plus and T-SPOT.TB than between QTF-GIT and T-SPOT.TB. However, we believe that the proportion of discrepancies between T-SPOT.TB and QTF-Plus is sufficiently important from a clinical point of view to justify the simultaneous use of 2 IGRA in this specific patient group.